Colin King joined Omega in August 2015 as Chief Operating Officer. He is responsible for directing and coordinating Group operational activities and achieving operational performance in accordance with policies and objectives established by the Board.
Mr King was Managing Director of Axis-Shield Diagnostics from 2007 until he joined Omega. He was responsible for leading their diversification strategy which was successful in maintaining revenues despite retiring two product revenue lines which accounted for 70% of turnover. Previously he held a number of positions within Axis-Shield encompassing project management, operations, planning and supply chain logistics.
Kieron Harbinson joined Omega in August 2002 as Finance Director. He is responsible for finance, information technology, human resources and operations planning.
Mr Harbinson joined Scotia Holdings plc in 1984. He qualified as an accountant in 1991, and became a Fellow of the Association of Chartered Certified Accountants in 1997. He was at the company for approximately 14 years, during which time he held various roles including Group Financial Controller and Chief Accountant. These roles enabled him to acquire a broad range of knowledge in a high growth technology company, and experience in corporate acquisitions, disposals and intellectual property matters. He also gained experience in various debt and equity transactions, and was involved in raising over £100 million for the company. He was also head of Tax and Treasury, responsible for a treasury programme of cash investments of over £50 million and management of currency exposures.
Mr Harbinson then joined Kymata Limited, a start up optoelectronics company as Finance Director. Over a period of 18 months, he was involved in raising approximately US$85 million of venture capital funding. He was responsible for implementing financial controls and accounting systems, over which time the company grew to over 200 employees by the time he left in 2000. The company was sold in 2001 to Alcatel for €134 million.
Jag Grewal joined Omega Diagnostics as Group Sales and Marketing Director in June 2011, having worked in diagnostics for over 20 years. He started his career as a Clinical Biochemist in the NHS, and developed his career in sales and marketing with Beckman Instruments, joining in 1995, and holding a variety of positions in sales, product management and marketing management.
In 2009, Mr Grewal joined Serco Health where he helped to create the first joint venture within UK pathology between Serco Health and Guys and St Thomas' Hospital NHS Foundation Trust. He is past Chairman and current treasurer of the British In-Vitro Diagnostics Association (BIVDA).
During his fourteen year career with Becton, Dickinson and Co., one of the world's leading suppliers of medical, diagnostic and life science research products, he held a number of senior leadership positions, and until the end of 2012, was BD's Senior Vice President, Corporate Strategy and Development, being responsible for BD's worldwide mergers and acquisitions and corporate strategies.
Previously, he was Worldwide President of BD Biosciences, a business segment with turnover of US$1.0 billion, including the provision of flow cytometry instruments and their associated reagents for CD4 testing used in a wide range of laboratory settings.
Prior to working for BD, Bill held senior business development positions with Pfizer Inc. and Johnson and Johnson.
Jeremy Millard joined Omega in March 2019 as Non-Executive Director.
Jeremy has 20 years investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy is currently a Non-Executive Director and chairman of the audit committee of AIM-listed Idox plc and a Non-Executive Director of AIM-listed Ilika Plc.